Skip to content
Peptigraph home

Are Peptides Legal? Where Each One Stands in 2026

It depends on the peptide. A few are FDA-approved prescription drugs. Some were taken off the FDA's safety-risk list this year, and an advisory committee backed six for compounding. Most are still unapproved.

Open the tracker
Not legal adviceStatus reflects public FDA and WADA records on the date shown. Rules differ by country and state.

2026 at a glance

FDA approved in our list
25
Removed from Category 2
12
On 15 Apr 2026
PCAC backed for 503A
6 of 7
23–24 Jul 2026; not final
Sellers sent warning letters
5
24 Aug 2026
Status

FDA approved

Approved drug products, prescription only. Approval covers the labelled uses.

Status

Backed for compounding, not final

The advisory committee voted for the 503A list in July 2026. The FDA has not finalized any of these votes.

Status

Removed from Category 2

Taken off the FDA's significant-safety-risk list on 15 Apr 2026. That is not an approval.

Status

Investigational

In clinical trials or awaiting an FDA decision in the US.

Status

Not approved

No FDA approval. Many are sold labelled “research use only”.

What a PCAC vote means

The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk drug substances pharmacies may compound. On 23–24 July 2026 it voted to recommend six peptides for the 503A bulks list: BPC-157, TB-500 and KPV (8–6 each), Semax (8–5), MOTS-c and Epitalon (7–5 each). It did not recommend DSIP.

The committee only advises. A peptide becomes legal to compound under 503A after the FDA adds it to the list through rulemaking, and the FDA has no deadline to act. None of the July 2026 votes has been finalized yet.

Changelog

What changed in 2026

Full tracker
  1. Retatrutide phase 3 TRIUMPH-1 results publishedTrial
  2. FDA warning letters to five research-peptide sellersEnforcement
  3. Eli Lilly sues six retatrutide sellersOther
  4. Health Canada wins a permanent injunction against an injectable-peptide sellerEnforcement
  5. Advisory committee backs 6 of 7 peptides for the 503A listPCAC vote
  6. Australia's TGA makes unapproved peptides a compliance priority (infringement notices, seizures, civil or criminal penalties)Enforcement
Pipeline

GLP-1 drugs in trials

All drugs in the pipeline tracker

Sources

  1. 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  3. 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
  4. 4Health Canada wins a permanent injunction against an injectable-peptide sellerHealth Canada · 2026canada.ca
  5. 5Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  6. 6Australia's TGA makes unapproved peptides a compliance priority (infringement notices, seizures, civil or criminal penalties)TGA · 2026tga.gov.auAccessed 2 Oct 2026
  7. 7FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  8. 8FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  9. 9Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
  10. 10Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  11. 11HHS signals about 14 Category 2 peptides may move toward Category 1PBS NewsHour · 2026pbs.org

Found an error? Report a correction.